Abstract P2-08-02: Trends in survival and the introduction of novel systemic therapies for locoregional and metastatic breast cancer in the Netherlands, 1989-2017

2020 ◽  
Author(s):  
Marianne Luyendijk ◽  
Otto Visser ◽  
Hedwig Blommestein ◽  
Carin Uyl- de Groot ◽  
Sabine Siesling
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
The Netherlands ◽  
Metastatic Breast ◽  
Systemic Therapies

scholarly journals Burden of early, advanced and metastatic breast cancer in The Netherlands

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
G. T. Vondeling ◽  
G. L. Menezes ◽  
E. P. Dvortsin ◽  
F. G. A. Jansman ◽  
I. R. Konings ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
The Netherlands ◽  
Metastatic Breast

scholarly journals Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
David B. Page ◽  
Harry Bear ◽  
Sangeetha Prabhakaran ◽  
Margaret E. Gatti-Mays ◽  
Alexandra Thomas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Clinical Practice ◽  
Clinical Data ◽  
Targeted Therapies ◽  
Metastatic Breast ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Better Than ◽  
Systemic Therapies

Abstract Antibodies blocking programmed death 1 (anti-PD-1) or its ligand (anti-PD-L1) are associated with modest response rates as monotherapy in metastatic breast cancer, but are generally well tolerated and capable of generating dramatic and durable benefit in a minority of patients. Anti-PD-1/L1 antibodies are also safe when administered in combination with a variety of systemic therapies (chemotherapy, targeted therapies), as well as with radiotherapy. We summarize preclinical, translational, and preliminary clinical data in support of combination approaches with anti-PD-1/L1 in metastatic breast cancer, focusing on potential mechanisms of synergy, and considerations for clinical practice and future investigation.

Sign in / Sign up

Export Citation Format

Share Document